Home » Entries posted by Hellenic Atherosclerosis Society
3rd International Conference on Lipid Science & Technology

3rd International Conference on Lipid Science & Technology

3rd International Conference on Lipid Science & Technology December 11-12, 2017 Rome, Italy Venue: Holiday Inn Rome Aurelia, Via Aurelia Km 8,400, 00165 Rome, Italy Theme: Unveiling the current frontiers in the field of lipidology Event url: http://lipids.conferenceseries.com/ Lipid Conferences will lay a platform for Lipidologists, Professors, Doctors, Biochemists, Molecular biologists and Scientists to discuss […]

International Atherosclerosis Research School August 20th – 25th, 2017 Prague, Czech Republic

International Atherosclerosis Research School August 20th – 25th, 2017 Prague, Czech Republic

International Atherosclerosis Research School August 20th – 25th, 2017 Prague, Czech Republic   Up close and personal with the Experts Cutting-edge Topics – Interdisciplinary Approach – Research and Treatment Training by Top Experts in the Field on a Face-To-Face Level –– Scientific Soft Skills How to Design Your Own Research– Evaluation of Papers Good Scientific […]

The relationship between leptin serum concentrations and hypertension in patients on the end stage of renal disease

The relationship between leptin serum concentrations and hypertension in patients on the end stage of renal disease

HJA | VOLUME 8 | ISSUE 1 | JANUARY – MARCH 2017 The relationship between leptin serum concentrations and hypertension in patients on the end stage of renal disease V.D. Raikou, D. Kyriaki

Effect of thrombin on human endothelial progenitor cells

Effect of thrombin on human endothelial progenitor cells

HJA | VOLUME 8 | ISSUE 1 | JANUARY – MARCH 2017 Effect of thrombin on human endothelial progenitor cells S. Papadaki, S. Sidiropoulou, V. Chantzichristos, M. Paschopoulos, A. Tselepis

The influence of diabetes on atherosclerosis and amyloid fibril formation of coronary arteries. A FT-IR spectroscopic study.

The influence of diabetes on atherosclerosis and amyloid fibril formation of coronary arteries. A FT-IR spectroscopic study.

HJA | VOLUME 8 | ISSUE 1 | JANUARY – MARCH 2017 The influence of diabetes on atherosclerosis and amyloid fibril formation of coronary arteries. A FT-IR spectroscopic study. Ch. Kotoulas, I. Mamarelis, E. Koutoulakis, M. Kyriakidou4, V. Mamareli, O. Tanis, E. Malesiou, T. Theophanides, J. Anastassopoulou

Atherosclerosis as a risk factor for dementia and Alzheimer’s disease

Atherosclerosis as a risk factor for dementia and Alzheimer’s disease

HJA | VOLUME 8 | ISSUE 1 | JANUARY – MARCH 2017 Atherosclerosis as a risk factor for dementia and Alzheimer’s disease V. Zacharopoulou, G. Zacharopoulou , K. Karkoulias, E. Tsampalas A. Lazakidou

Slide set | 2016 ESC/EAS Guidelines on the management of dyslipidaemias.

Slide set | 2016 ESC/EAS Guidelines on the management of dyslipidaemias.

  Slide set | 2016 ESC/EAS Guidelines on the management of dyslipidaemias. Publication in full here

Low-density lipoproteins cause atherosclerotic cardiovascular disease (ASCVD) | EAS Consensus Panel

Low-density lipoproteins cause atherosclerotic cardiovascular disease (ASCVD) | EAS Consensus Panel

2016 European Guidelines on cardiovascular disease prevention in clinical practice.

2016 European Guidelines on cardiovascular disease prevention in clinical practice.

2016 European Guidelines on cardiovascular disease prevention in clinical practice. The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation […]

ESC/EAS Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk

ESC/EAS Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk

Introduction Atherosclerotic cardiovascular disease (ASCVD) underlies the thrombotic events intimately associated with myocardial infarction, a significant proportion of ischaemic strokes, as well as critical limb ischaemia. Such events confer substantial mortality, physical and/or mental disability, and cost for the individual and society. Indeed, no finite value can be attributed to the cost to the individual, […]

Page 1 of 11123Next ›Last »